Clinical Trials

To meet the need for safer and more effective treatments for canine cancer, EVVIVAX is conducting clinical trials in collaboration with the University of Pisa, Italy and VOS (Veterinary Oncology Service), New York, USA:

Tel-eVax

AAHSD000080 
Evaluating a targeted Telomerase vaccine to stimulate anti-tumor immunity and prolong survival times in dogs and cats with various cancers – Species: Canine and Feline

 

Erb-eVax

AAHSD000081 
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with osteosarcoma (bone cancer) – Species: Canine

AAHSD000082
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with mammary adenocarcinoma (bone cancer) – Species: Feline

AAHSD000085 
Evaluating a targeted her2/neu cancer vaccine for the stimulation of anti-tumor immunity and prolonging survival times in dogs with transitional cell carcinoma (bladder or prostate cancer). Species: Canine

 

Details are available at AVMA Animal Health Studies Database (AAHSD).

 

Additional trials for other cancer types are in development